Beta-bloqueante

Applications A labelled metabolite of Pitavastatin. Recent studies have shown that conversion between acid and lactone forms occurs in the body, drug-drug interaction should be considered on both acid and lactone forms. The inhibitory effects of statins on CYP metabolic activities and MDR1 transporting activity were investigated using human liver microsomes and MDR1-overexpressing LLC-GA5-COL150 cells. References Wang, J., et al.: Drug Metab. Dispos., 30, 1352 (2002), Yamada, I., et al.: Xenobiotica, 33, 789 (2003), Fujino, H., et al.: Xenobiotica, 34, 961 (2004), Ando, H., et al.: Br. J. Clin. Pharmacol., 60, 494 (2005),

Applications Used as an antihypertensive and antianginal. References Gross, G.J., et al.: Gen. Pharmacol., 14, 677 (1983), Molyvdas, P.A. and Sperelakis, N.: J. Cardiovasc. Pharmacol., 8, 449 (1986), Mizuno, K., et al.: Res. Comm. Chem. Pathol. Pharmacol., 52, 3 (1986)

Stability Hygroscopic Applications A novel membrane-permeant allosteric effector of hemoglobin (Hb), enhances the regulated oxygen release capacity of red blood cells, thus counteracting the effects of hypoxia in diseases such as cancer and cardiovascular ailments. References Duarte,C.D. et al.: Chembiochem., 11, 2543 (2010); Biolo, A. et al.: Proc. Nat. Acad. Sci. U.S.A., 106, 1926 (2009);

Applications Norepinephrine Sulfonic Acid is a derivative of DL-Norepinephrine Hydrochloride (N674500), antagonist of dibutyryl cyclic-AMP in the regulation of narcosis. Norepinephrine modulates human dendritic cell activation by altering cytokine release. Not a dangerous good if item is equal to or less than 1g/ml and there is less than 100g/ml in the package References Piguet, P., et al.: J. Exp. Med., 173, 673 (1991), Hosoi, J., et al.: Nature, 363, 159 (1993), Elenkov, I., et al.: Pharmacol. Rev., 52, 595 (2000), Kaplan, D., et al.: Immunity, 23, 611 (2005),

Applications Benazepril-d5 Hydrochloride is the labeled analogue of Benazepril Hydrochloride (B119750), which is used as an antihypertensive; angiotensin converting enzyme inhibitor. References Schaller, M.D., et al.: Eur. J. Clin. Pharmacol., 28, 267 (985); Colfer, H.T., et al.: Am. J. Cardiol., 70, 354 (1992)

Applications Labelled Dabigatran (D100090). Nonpeptide, direct thrombin inhibitor. Antithrombotic. References Hauel, N., et al.: J. Med. Chem., 45, 1757 (2002), Mungall, D., et al.: Curr. Opin. Invest. Drugs, 3, 095 (2002), Stangier, J., et al.: J. Clin. Pharmacol., 45, 555 (2005),

Impurity Atenolol EP Impurity A Applications 4-(Hydroxyphenyl)acetamide (Atenolol EP Impurity A) is used as an intermediate for the synthesis of Atenolol (A790075) and various other organic compounds and pharmaceuticals. It is a process impurity for Atenolol (A790075) References Inkum, R., et al.: Maejo Int. J. Sci. Tech., 6, 372 (2012); Pai, N.R., et al.: J. Chem. Pharma. Rsch., 4, 375 (2012); Moon, J.T., et al.: Bio-org. Medn. Chem., 20, 734 (2012);

Sulfonamides used as drugs